Pioneering diagnostics
E.g., 27/02/2017
E.g., 27/02/2017

bioMérieux’s VIDAS® B•R•A•H•M•S PCT™ becomes the first FDA-cleared procalcitonin assay as an aid for antibiotic stewardship in respiratory infections and sepsis

24 February, 2017

bioMérieux, a world leader in the field of in vitro diagnostics, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the expanded use of VIDAS® B•R•A•H•M•S PCT™, an automated...

bioMérieux – Fourth-Quarter 2016 Business Review

19 January, 2017

  • Remarkable growth in sales in 2016, up 9.6% like-for-like, lifted by all regions and all strategic lines:
    • €2,103 million in sales
    • Up 7.1% as reported
    • ...

bioMérieux and Banyan Biomarkers Partner to Develop, Validate and Market Blood-Based Biomarkers for Traumatic Brain Injury

19 January, 2017

bioMérieux, a world leader in the field of in vitro diagnostics and Banyan Biomarkers, an innovative biomarkers company developing blood tests capable of diagnosing traumatic brain injuries (TBI), announced today that they have entered into a partnership. Under the terms of the...

bioMérieux launches eMAG®, a new generation automated system for the extraction of DNA and RNA

10 November, 2016

bioMérieux, a world leader in the field of in vitro diagnostics, has announced the launch of eMAG®, its new molecular biology platform for the extraction of nucleic acids (DNA, RNA).

eMAG® builds on the quality, robustness and ease of use that have...

Pierre Boulud appointed Corporate Vice President of the Asia Pacific region at bioMérieux

Marcy l’Étoile, France – November 7, 2016 – bioMérieux, a world leader in the field of in vitro diagnostics, has announced the appointment of Pierre Boulud to the position of Corporate VP in charge of the Asia Pacific region as of November 2. He joins the Executive Committee of bioMérieux and will report directly to Alexandre Mérieux, CEO. 

07 November, 2016

Pierre Boulud will also be in charge of bioMérieux’s portfolio and strategic planning starting on January 1, 2017.

Before joining bioMérieux, Pierre Boulud worked for 14 years at Ipsen pharmaceutical company, where he held various positions, in particular as the head of the...

bioMérieux – Business Review for the nine months ended September 30, 2016

20 October, 2016

 
  • 10.3% organic sales growth for the first nine months of 2016, powered by the Americas and Asia-Pacific regions:
    • Sales reached €1,512 million
    • Up 7.1% as reported
  • All strategic lines contributed to the dynamic performance
  • ...

Lyme disease diagnostic tests

17 October, 2016

Like other laboratories, bioMérieux has been summoned to appear before the Tribunal de Grande Instance de Paris by 45 patients to obtain compensations linked to anxiety allegedly “generated by a lack of reliability of serodiagnostic tests” for Lyme disease.
 ...

FilmArray® Respiratory Panel EZ is CLIA waived by the FDA

11 October, 2016

bioMérieux, a world leader in the field of in vitro diagnostics, announced that BioFire Diagnostics, LLC, its molecular biology affiliate, received U.S. Food and Drug Administration (FDA) 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver for the FilmArray...

BIOASTER, bioMérieux, ESPCI, GSK, Hospices Civils de Lyon and Sanofi join forces against sepsis 

10 October, 2016

BIOASTER, the French accelerator of microbiology technology innovation, bioMérieux, ESPCI (College of Physics and Industrial Chemistry of the city of Paris), GSK, the Hospices Civils de Lyon (HCL) and Sanofi announce that they are combining their expertise to fight against sepsis within REALISM...

bioMérieux introduces EviSight™ Compact, a new automated diagnostic solution for microbial detection in pharmaceutical production

06 October, 2016

bioMérieux, a world leader in the field of industrial microbiological control, announces the launch of EviSight™ Compact, an intelligent incubator system providing real time culture media reading. For use in pharmaceutical industry R&D and production settings, EviSight™...